Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review

Abstract

Introduction

The study evaluates the first-line application of pembrolizumab in metastatic non-small-cell lung cancer (mNSCLC), head and neck squamous cell cancer (HNSCC), gastric cancer, and renal cell carcinoma. Utilizing the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the American Society of Clinical Oncology Value Framework (ASCO-VF), the analysis incorporates data from pivotal KEYNOTE trials.

Methods

The study systematically assessed the clinical benefit of pembrolizumab in advanced solid malignancies through nine randomized controlled trials, one of which comprised two experimental arms. Data extraction from primary sources was conducted from PubMed, ASCO, and ESMO publications. Utilizing ESMO-MCBS and ASCO-VF forms, the evaluation focused on clinical benefit, toxicity, and bonus points, with discrepancies resolved through consensus discussions.

Results

Nine first-line indications for pembrolizumab received Food and Drug Administration approval for metastatic solid tumors between 2018 and 2023. Notable distinctions in ESMO-MCBS grades revealed seven trials with substantial clinical benefit (grades 5 to 4) and three with moderate to negligible benefit (grades 3 to 1). Bonus points, primarily based on the tail of the curve, were allocated to three trials for overall survival, one for progression-free survival, and one for a significant improvement in quality of life.

Conclusions

Our evaluation of pembrolizumab across diverse cancers, especially in mNSCLC and HNSCC, revealed varied outcomes and challenges in clinical benefit interpretation. The assessment of clinical benefit, incorporating quantitative and qualitative endpoints, underscores the need to consider survivorship outcomes and patient perspectives for a comprehensive understanding.

Keywords

Pembrolizumab immune checkpoint inhibitors advanced solid tumors clinical benefit ESMO-MCBS ASCO-VF

Get full access to this article

View all access options for this article.

References

Bachelard

Coquan

du Rusquec

, et al. Risks and benefits of anticancer drugs in advanced cancer patients: a systematic review and meta-analysis. EClinicalMedicine 2021; 40: 101130. Available from: https://www.sciencedirect.com/science/article/pii/S2589537021004107.

Howie

Peppercorn

. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol 2013; 5: 318–323.

Clarke

Johnston

Corrie

, et al. Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer 2015; 15: 892.

Johnson

Nebhan

Moslehi

, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022; 19: 254–267. Available from: https://www.nature.com/articles/s41571-022-00600-w.

Rinde

. Debating value versus cost for immunotherapy. OncologyLive 2018; 19, Available from: https://www.onclive.com/view/debating-value-versus-cost-for-immunotherapy.

Shin

Kumar

Guo

. Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021. Clin Drug Investig 2023; 43(4): 289–298. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066981/.

Slomiany

Madhavan

Kuehn

, et al. Value frameworks in oncology: comparative analysis and implications to the pharmaceutical industry. Am Health Drug Benefits 2017; 10: 253–260. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620505/.

Campolina

. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks. Clinics 2018; 73: e470s. Available from: https://linkinghub.elsevier.com/retrieve/pii/S180759322201122X.

du Rusquec

de Calbiac

Robert

, et al. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res 2019; 11: 4297–4312. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527794/.

10.

Merck Sharp & Dohme LLC. KEYTRUDA® (pembrolizumab) injection, for intravenous use. 2023 [cited 2024 Jan 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf.

11.

Cherny

Dafni

Bogaerts

, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol 2017; 28: 2340–2366. Available from: https://pubmed.ncbi.nlm.nih.gov/28945867/.

12.

American Society of Clinical Oncology (ASCO). ASCO Value Framework. 2020 [cited 2024 Jan 2]. Available from: https://old-prod.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/value-cancer-care.

13.

Cherny

Sullivan

Dafni

, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547–1573. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)31868-X/fulltext.

14.

Schnipper

Davidson

Wollins

, et al. Updating the American society of clinical oncology value framework: revisions and reflections in response to comments received. JCO 2016; 34: 2925–2934. Available from: https://ascopubs.org/doi/full/10.1200/JCO.2016.68.2518.

15.

Cherny

de Vries

EGE

Dafni

, et al. Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score. JCO 2019; 37: 336–349. Available from: https://ascopubs.org/doi/10.1200/JCO.18.00729.

16.

U.S. Food and Drug Administration. FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC. FDA. 2018 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic.

17.

U.S. Food and Drug Administration. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. FDA. 2018 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc.

18.

U.S. Food and Drug Administration. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%). FDA. 2019 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1.

19.

U.S. Food and Drug Administration. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. FDA. 2019 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma.

20.

U.S. Food and Drug Administration. FDA amends pembrolizumab’s gastric cancer indication. FDA. 2023 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication.

21.

U.S. Food and Drug Administration. FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma. FDA. 2023 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction.

22.

U.S. Food and Drug Administration C for DE. FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. FDA. 2019 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma.

23.

U.S. Food and Drug Administration. FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma. FDA. 2021 [cited 2024 Jan 11]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma.

24.

Delgado

Guddati

. Clinical endpoints in oncology – a primer. Am J Cancer Res 2021; 11: 1121. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085844/.

25.

Moon

Chen

. Defining a clinically meaningful benefit in cancer clinical trials: from the perspectives of the clinical trialist, patient, and society. JNCI Cancer Spectrum 2018; 2, Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649690/.

26.

Rodríguez-Abreu

Powell

Hochmair

, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol 2021; 32: 881–895. Available from: https://www.annalsofoncology.org/article/S0923-7534(21)01146-7/fulltext.

27.

Paz-Ares

Vicente

Tafreshi

, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 2020; 15: 1657–1669. Available from: https://www.jto.org/article/S1556-0864(20)30500-1/fulltext.

28.

de Castro

Kudaba

, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non–small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol 2023; 41: 1986–1991. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082298/.

29.

Reck

Rodríguez-Abreu

Robinson

, et al. Five-year outcomes with Pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. JCO 2021; 39: 2339–2349. Available from: https://ascopubs.org/doi/10.1200/JCO.21.00174.

30.

Harrington

Burtness

Greil

, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. JCO 2023; 41: 790–802. Available from: https://ascopubs.org/doi/full/10.1200/JCO.21.02508.

31.

Güven

Thong

Arndt

. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review. J Cancer Surviv 2024. https://doi.org/10.1007/s11764-023-01507-w

32.

Janjigian

Kawazoe

Bai

, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023; 402: 2197–2208. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02033-0/fulltext.

33.

Rha

Yañez

, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181–1195. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext.

34.

Powles

Plimack

Soulières

, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21: 1563–1573. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30436-8/fulltext.

35.

Motzer

Alekseev

Rha

, et al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med 2021; 384: 1289–1300.

36.

Bedke

Rini

Plimack

, et al. Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol 2022; 82: 427–439. Available from: https://www.europeanurology.com/article/S0302-2838(22)02457-5/fulltext.

37.

Motzer

Porta

Alekseev

, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 2022; 23: 768–780. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00212-1/fulltext.